Rifamycin SV versus triamcinolone in local treatment of rheumatoid synovitis.
This study was aimed to evaluate the usefulness of rifamycin SV as an agent for local treatment of rheumatoid synovitis. Rifamycin SV was compared with triamcinolone acetonide in a randomized controlled trial on 87 patients with rheumatoid arthritis and with persistent knee synovitis. The treatment with rifamycin consisted of several weekly intra-articular injections, whereas triamcinolone was given as a single intra-articular injection. At the end of the therapy, 27 (61.4%) of the 44 rifamycin patients and 39 (91%) of the 43 steroid patients responded well to the treatment, and this difference was significant (p < 0.01). Rifamycin SV was responsible for unpleasant local side effects in all cases. In both groups, after 1 year of follow-up the synovitis had relapsed in about 42% of cases. We conclude that rifamycin SV is less useful than triamcinolone acetonide in the local treatment of rheumatoid synovitis.
Marchesoni
A
A
Chair of Rheumatology, University of Milan, Istituto Ortopedico G. Pini, Italy.
Sinigaglia
L
L
Ranza
R
R
Varenna
M
M
Battafarano
N
N
Tosi
S
S
D000328:Adult; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007270:Injections, Intra-Articular; D008297:Male; D012294:Rifamycins / Q000009:adverse effects / Q000627:therapeutic use*; D013585:Synovitis / Q000188:drug therapy*; D014221:Triamcinolone / Q000009:adverse effects / Q000627:therapeutic use*
D012294:Rifamycins; D014221:Triamcinolone; C023808:rifamycin SV